Updated from 2:50 p.m. EDT Shares of Vernalis ( VNLS) were easily among the best-performing health care stocks Wednesday, after the U.K.-based company announced a licensing agreement with Endo Pharmaceuticals ( ENPD). Vernalis will license its Frova migraine drug to Endo Pharmaceuticals in exchange for an up-front fee of $30 million, anniversary payments for the first two years of $15 million each year and a $40 million milestone payment contingent upon Frova winning Food and Drug Administration approval for menstruation-associated migraine. The milestone payments increase as specific sales targets are reached. In all, milestone payments could total as much as $255 million. Shares of Vernalis traded up $2.39, or 136.6%, to $4.14. Neurocrine Biosciences ( NBIX) rose after the company said it would submit new drug applications for its insomnia treatment to the FDA early in the fourth quarter. One application will be submitted for an immediate-release formulation of the drug and one for a modified release version. The company said that based on all completed clinical studies there are no safety issues that would deter it from filing the applications with the FDA. Shares of Neurocrine Biosciences traded up $3.69, or 7.7%, to $51.69. Shares of Bruker Biosciences ( BRKR) fell after the company reduced its earnings and sales outlook for the second quarter. It now expects to report a loss of 3 cents to 5 cents a share vs. previous guidance of break-even to 2 cents a share. It also said that sales would now be in the range of $63 million to $65 million vs. previous guidance of between $70 million and $74 million. Analysts polled by Thomson First Call had expected it to earn 1 cent a share on sales of $71.6 million. Bruker said a longer sales cycle led to the second-quarter shortfall. Shares of Bruker Biosciences traded down 55 cents, or 11.6%, to $4.20.